bioMérieux S.A. Experiences Notable Rise in Short Interest

bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report) has experienced a considerable rise in short interest during the month of November. As of November 30th, the total short interest reached 139,000 shares, which marks a notable increase of 6.6% from the figure of 130,400 shares recorded on November 15th. Given the average trading volume of 100 shares, the short-interest ratio is currently calculated at an impressive 1,390.0 days.

Analysts Set New Price Targets

In a related note, UBS Group has upgraded the shares of bioMérieux, assigning a "strong-buy" rating in a research report published on August 22nd.

bioMérieux Stock Moves Up 0.9%

In mid-day trading on Friday, shares of OTCMKTS:BMXMF saw an increase of $0.93, reaching $107.03. A total of 140 shares were exchanged, which is below the average trading volume of 337 shares. Currently, bioMérieux boasts a 50-day moving average price of $108.32 and a two-hundred-day moving average price of $107.55. The stock's 12-month low stands at $93.50, while its 12-month high is $122.52.

About bioMérieux

bioMérieux S.A. specializes in the development and manufacturing of in vitro diagnostic solutions aimed at diagnosing infectious diseases. Their products cater to markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. bioMérieux's systems utilize various biological samples—such as blood, saliva, and urine—to diagnose a range of infectious diseases, including those caused by bacteria, parasites, and viruses. Additionally, the company focuses on microbiological control for the food, pharmaceutical, and cosmetic industries.

Featured Articles

• Five stocks we like better than bioMérieux
• Short Selling: How to Short a Stock
• Dave & Buster’s: Is It Time to Make Another Play on This Stock?
• P/E Ratio Calculation: How to Assess Stocks
• Why Hershey Stock Has More Room to Run Despite Takeover Rejection
• NYSE Stocks Give Investors a Variety of Quality Options
• Texas Instruments: The Old-School Tech Titan Still Delivering

This news alert was generated using advanced technology to provide readers with timely and accurate information, and it has been reviewed for accuracy before publication.

Should You Invest $1,000 in bioMérieux Now?

Before making any investment decisions regarding bioMérieux, it is vital to gather all necessary insights.

Market analysts consistently monitor and report on top-performing stocks, and presently, bioMérieux is not featured among their most recommended investments. Despite holding a "Strong Buy" rating from several analysts, there are five other stocks that have been highlighted as superior investment options at this time.

Explore these five alternative stocks for more informed decision-making.

bioMérieux, growth, stocks